About This Page
This is a clinician-written, evidence-based summary aligned to the USMLE Step 2 CK Content Outline. It is intended for medical students preparing for USMLE Step 2 CK. Management reflects current ACC/AHA, USPSTF, and APA guidelines. Always cross-reference with UpToDate, institutional protocols, and clinical judgment.
The Bottom Line
- ADHD requires symptoms before age 12, impairment in more than one setting, and exclusion of alternative explanations
- Use validated parent and teacher rating scales; diagnosis is clinical, not based on imaging or labs
- Preschool children: parent training in behavior management is first-line; methylphenidate may be used if severe persistent impairment
- School-age children and adolescents: FDA-approved ADHD medications plus school/behavioral interventions
- Assess comorbid learning disorders, anxiety, depression, sleep problems, substance use, trauma, and tics
Overview
ADHD is characterized by developmentally inappropriate inattention, hyperactivity, and impulsivity causing impairment. The AAP guideline covers children and adolescents aged 4-18 years. Management is multimodal: accurate diagnosis, education, behavioral interventions, classroom supports, and medication when indicated. Step 2 CK commonly tests age-specific first-line treatment and differentiating ADHD from normal behavior, anxiety, sleep deprivation, absence seizures, lead exposure, and trauma.
Epidemiology
ADHD is one of the most common neurodevelopmental disorders of childhood. It is more frequently diagnosed in boys, though girls may present with inattentive symptoms and be underrecognized. Symptoms often persist into adolescence and adulthood, and comorbid learning and psychiatric disorders are common.
Clinical Features
Symptoms
Inattention: careless mistakes, difficulty sustaining attention, disorganization, forgetfulness, loses things
Hyperactivity/impulsivity: fidgets, leaves seat, interrupts, talks excessively, difficulty waiting turn
Functional impairment at school, home, or peer settings
Sleep disturbance, anxiety, depression, substance use, trauma exposure, or learning difficulty mimicking ADHD
Chest pain, syncope, palpitations, or family history of sudden cardiac death before stimulant use
Signs
Normal physical exam is common
Poor academic performance despite adequate intelligence or effort
Tics, anxiety, oppositional behavior, or mood symptoms may coexist
Hypertension, tachycardia, poor growth, or appetite suppression during stimulant therapy
Neurologic abnormalities or developmental regression suggest another diagnosis
Investigations
First-line
Validated rating scalesParent and teacher Vanderbilt or similar scales assess DSM symptoms, impairment, and comorbidities
Multi-setting historySymptoms and impairment must occur in more than one setting
Screen for comorbiditiesLearning disorders, anxiety, depression, ODD/conduct disorder, sleep apnea, substance use, trauma, autism, and seizures
Second-line
School evaluationAssess learning disability and implement IEP/504 supports when eligible
Targeted medical testingNo routine labs/imaging; test hearing/vision, lead, thyroid, or sleep disorder only when suggested
Cardiac assessmentHistory and exam before stimulants; ECG only if concerning cardiac history/exam or risk factors
Specialist
Behavioral health/developmental pediatricsDiagnostic uncertainty, preschool severe symptoms, complex comorbidity, treatment resistance, or safety concerns
CardiologyKnown structural heart disease or concerning syncope/palpitations/family history before stimulant therapy
1
Preschool age 4-5 years
- First-line: evidence-based parent training in behavior management and/or behavioral classroom interventions
- Methylphenidate may be considered if behavioral interventions are insufficient and impairment remains moderate to severe
- Confirm symptoms are not better explained by sleep, language delay, trauma, autism, or environmental mismatch
2
Elementary and middle school age 6-12 years
- FDA-approved ADHD medication plus parent training/behavioral classroom intervention
- Stimulants have strongest evidence: methylphenidate or amphetamine formulations
- Coordinate school supports, daily report cards, organizational skills, and classroom accommodations
3
Adolescents 12-18 years
- FDA-approved ADHD medication with adolescent assent and monitoring for misuse/diversion
- Behavioral and educational supports remain important
- Screen for depression, anxiety, substance use, sleep, driving risk, and adherence
4
Medication monitoring
- Monitor height, weight, appetite, sleep, BP, HR, mood, tics, and symptom response
- Nonstimulants include atomoxetine, guanfacine ER, clonidine ER, and viloxazine depending profile
- Titrate to maximum benefit with tolerable adverse effects rather than fixed low dose
Complications
- Academic failure: Untreated ADHD can impair school performance and self-esteem
- Injury risk: Impulsivity increases accidents and risk-taking
- Substance misuse and diversion: Adolescents require monitoring and safe medication storage
- Medication adverse effects: Appetite suppression, insomnia, abdominal pain, headache, BP/HR increases, mood effects
- Missed comorbidity: Anxiety, depression, learning disorder, trauma, and sleep disorder can drive persistent impairment
USMLE Step 2 CK Exam Tips
- 1ADHD diagnosis requires impairment in at least two settings — parent report alone is not enough
- 2Preschool first-line = parent training/behavior therapy, not immediate stimulant as the only intervention
- 3School-age ADHD first-line includes stimulant medication plus behavioral/school supports
- 4No routine brain imaging, EEG, or labs for typical ADHD
- 5Screen for sleep problems and learning disorders before escalating medication
- 6Stimulants can decrease appetite and slow weight gain; monitor growth and vitals
- 7Adolescents need assessment for diversion, substance use, depression, and driving risk
practicetest your knowledge on adhd (pediatric management)Apply what you've learnt with USMLE Step 2 CK-style questions from the iatroX Q-Bank — pediatrics and beyond.
open q-bank